Alzheimer's research & therapy Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Perceptions about dementia clinical trials among underrepresented populations: a nationally representative survey of U.S. dementia caregivers..  16:-. 2024
• Association of education attainment, smoking status, and alcohol use disorder with dementia risk in older adults: a longitudinal observational study..  16:-. 2024
• Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration..  16:-. 2024
• A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease..  16:-. 2024
• Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration..  16:-. 2024
• Lower in vivo locus coeruleus integrity is associated with lower cortical thickness in older individuals with elevated Alzheimer's pathology: a cohort study..  16:-. 2024
• Locus coeruleus integrity and left frontoparietal connectivity provide resilience against attentional decline in preclinical alzheimer's disease..  16:-. 2024
• A novel spatiotemporal graph convolutional network framework for functional connectivity biomarkers identification of Alzheimer's disease..  16:-. 2024
• Polygenic effects on the risk of Alzheimer's disease in the Japanese population..  16:-. 2024
• Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis..  16:-. 2024
• Identification of high likelihood of dementia in population-based surveys using unsupervised clustering: a longitudinal analysis..  15:-. 2023
• Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease..  15:-. 2023
• Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants..  15:-. 2023
• The therapeutic landscape of tauopathies: challenges and prospects..  15:-. 2023
• In vivo cortical diffusion imaging relates to Alzheimer's disease neuropathology..  15:-. 2023
• The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury..  15:-. 2023
• Network analysis of neuropsychiatric symptoms in Alzheimer's disease..  15:-. 2023
• Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment..  15:-. 2023
• Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease..  14:-. 2022
• Anticipated reactions to learning Alzheimer's disease biomarker results..  14:-. 2022
• The role of basket trials in drug development for neurodegenerative disorders..  14:-. 2022
• Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease..  14:-. 2022
• Relationship of sex differences in cortical thickness and memory among cognitively healthy subjects and individuals with mild cognitive impairment and Alzheimer disease..  14:-. 2022
• Intracranial internal carotid artery calcification is not predictive of future cognitive decline..  14:-. 2022
• Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping..  14:-. 2022
• Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease..  14:-. 2022
• Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study..  13:-. 2021
• Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease..  13:-. 2021
• Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer's dementia..  13:-. 2021
• Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project..  13:-. 2021
• Verbal intelligence is a more robust cross-sectional measure of cognitive reserve than level of education in healthy older adults..  13:-. 2021
• Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease..  13:-. 2021
• GPS driving: a digital biomarker for preclinical Alzheimer disease..  13:-. 2021
• Quality of opioid prescribing in older adults with or without Alzheimer disease and related dementia..  13:-. 2021
• Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?.  13:-. 2021
• The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status..  13:-. 2021
• Detecting Alzheimer's disease biomarkers with a brief tablet-based cognitive battery: sensitivity to Aβ and tau PET..  13:-. 2021
• High-intensity exercise and cognitive function in cognitively normal older adults: a pilot randomised clinical trial..  13:-. 2021
• Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study..  13:-. 2021
• Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum..  12:-. 2020
• The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease..  12:-. 2020
• Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease..  12:-. 2020
• Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis..  12:-. 2020
• Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer's and non-Alzheimer's dementia..  12:-. 2020
• Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification..  12:-. 2020
• Souvenaid in the management of mild cognitive impairment: an expert consensus opinion..  11:-. 2019
• A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain..  11:-. 2019
• Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer's disease..  11:-. 2019
• Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease..  11:-. 2019
• Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments..  11:-. 2019
• Utility of the Dependence Scale in dementia: validity, meaningfulness, and health economic considerations..  10:-. 2018
• Personalized predictive modeling for patients with Alzheimer's disease using an extension of Sullivan's life table model..  9:-. 2017
• On the path to 2025: understanding the Alzheimer's disease continuum..  9:-. 2017
• Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study..  8:-. 2016
• A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans..  8:-. 2016
• An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter..  7:-. 2015
• Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease..  7:-. 2015
• Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants..  7:-. 2015
• Is the risk of Alzheimer's disease and dementia declining?.  7:-. 2015
• Principles and management of neuropsychiatric symptoms in Alzheimer's dementia..  7:-. 2015
• Elevated cerebrovascular resistance index is associated with cognitive dysfunction in the very-old..  7:-. 2015
• Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort..  7:-. 2015
• Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels..  6:-. 2014
• Open questions for Alzheimer's disease immunotherapy..  6:-. 2014
• Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review..  5:-. 2013
• Dementia in the oldest old: a multi-factorial and growing public health issue..  5:-. 2013
• Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?.  5:-. 2013
• Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease..  5:-. 2013
• Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems..  5:-. 2013
• Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study..  4:-. 2012
• Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis..  4:-. 2012
• Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains..  4:-. 2012
• Recent Alzheimer's disease research highlights..  4:-. 2012
• Right sizing funding for Alzheimer's disease..  3:-. 2011
• Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease..  3:-. 2011
• Pro: Can biomarkers be gold standards in Alzheimer's disease?.  2:-. 2010
• Vascular health, diabetes, APOE and dementia: the Aging, Demographics, and Memory Study..  2:-. 2010
• Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases..  1:-. 2009
• Welcome to Alzheimer's research & therapy..  1:-. 2009
• Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment 2020
• Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment 2020
• Perceptions about dementia clinical trials among underrepresented populations: a nationally representative survey of U.S. dementia caregivers

Identity

International Standard Serial Number (ISSN)

• 1758-9193